Future Landscape: Collaboration for Patients With Relapsed/Refractory Multiple Myeloma
Discover how the treatment landscape for relapsed/refractory myeloma is evolving through collaboration between academic centers and community oncologists, offering patients access to innovative therapies and clinical trials.
EP: 1.Patient Case: A 76-Year-Old Man with Pentarefractory Multiple Myeloma
EP: 2.Immunologic Therapies in Multiple Myeloma: Expert Insights
EP: 3.Impact of Teclistamab on the Management of Relapsed/Refractory Multiple Myeloma
EP: 4.Talquetamab and Elranatamab: Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
EP: 5.Choosing Between CAR T and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
EP: 6.Patient-Centered Approach to Managing Bispecific Antibody Therapy
EP: 7.Navigating Unmet Needs and Challenges in Multiple Myeloma Treatment
EP: 8.Future Landscape: Collaboration for Patients With Relapsed/Refractory Multiple Myeloma
Transcript:
David M. Dingli, MD, PhD: The treatment of relapsed/refractory myeloma has been revolutionized with these agents. We need to learn how to use them. We need to offer them to patients with this disease. The patient who is relapsing, if they’ve never been seen in a large center, should be referred as soon as possible. The academic centers and the community oncologists are in partnership in taking care of these patients. The earlier the patient is seen, the better it is. Because we can help the community oncologists find optimal therapeutic options for the patient. Many patients are interested in participating in clinical trials that can be offered. This is how these products have all become available. Please consider referring patients early in relapse.
I also believe that patients with myeloma should always be seen in the center of excellence. Even earlier on, to make determinations about transplantation, make determinations about risk stratification and optimization of therapy. Then the patient can continue to be seen in collaboration between the academic center and the local community oncologist. But in particular, this has become an important consideration in the relapsed/refractory setting if we’re going to use these products together to treat patients with this disease.
Transcript is AI-generated and edited for readability.
